Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | USP1 | O94782 | 2/20 | 0.47 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.46 |
| ▸ | METAP1 | P53582 | 3/20 | 0.42 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128983 | 0.90 | KMT2A (0.50) | KMT2AMEN1NPC1PDE5AUSP1 | |
| SCHEMBL5113662 | 0.90 | PDE5A (0.47) | KMT2AMEN1NPC1PDE5AHIF1A | |
| SCHEMBL5122329 | 0.89 | ICAM1 (0.48) | KMT2AMEN1NPC1PDE5AUSP1 | |
| SCHEMBL5122691 | 0.87 | KMT2A (0.63) | KMT2AMEN1NPC1PDE5AHIF1A | |
| SCHEMBL5128521 | 0.87 | ADORA2A (0.49) | USP1WDR48ADORA2AADORA1 | |
| SCHEMBL5115640 | 0.87 | MEN1 (0.54) | KMT2AMEN1NPC1PDE5AUSP1 | |
| SCHEMBL5123197 | 0.85 | USP1 (0.54) | KMT2AMEN1NPC1PDE5AUSP1 | |
| SCHEMBL5124391 | 0.85 | MEN1 (0.45) | KMT2AMEN1NPC1PDE5AUSP1 | |
| SCHEMBL5130006 | 0.84 | MEN1 (0.52) | KMT2AMEN1NPC1PDE5AHIF1A | |
| SCHEMBL5815313 | 0.84 | HIF1A (0.41) | KMT2AMEN1NPC1PDE5AUSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | KMT2A 388/4885MEN1 696/4885NPC1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.